Ixabepilone for the treatment of solid tumors: a review of clinical data
- PMID: 18321240
- DOI: 10.1517/13543784.17.3.423
Ixabepilone for the treatment of solid tumors: a review of clinical data
Abstract
Background: Microtubule stabilizing agents such as taxanes are an integral part of therapy for multiple solid tumors. However, due to limitations of these agents, newer more effective cytotoxic agents are necessary. Ixabepilone, an epothilone B analog, is a novel microtubule stabilizing agent.
Objective: This review provides an updated summary of emerging clinical experience with Ixabepilone.
Methods: Phase I, II and III clinical trials presented in abstract form or journal articles found within a PubMed search through November 2007 are described in this review.
Results/conclusion: Ixabepilone offers promising clinical activity in a variety of solid tumors. Ixabepilone is FDA-approved for the treatment of breast cancer refractory to anthracyclines and taxanes. The optimal dose and schedule are still being defined, and the predominant side effects are bone marrow suppression and neuropathy.
Similar articles
-
Ixabepilone, a novel epothilone analog in the treatment of breast cancer.Expert Opin Investig Drugs. 2008 Apr;17(4):593-9. doi: 10.1517/13543784.17.4.593. Expert Opin Investig Drugs. 2008. PMID: 18363523 Review.
-
Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer.Expert Opin Drug Metab Toxicol. 2015 Jul;11(7):1177-85. doi: 10.1517/17425255.2015.1057497. Expert Opin Drug Metab Toxicol. 2015. PMID: 26073581 Review.
-
Preclinical discovery of ixabepilone, a highly active antineoplastic agent.Cancer Chemother Pharmacol. 2008 Dec;63(1):157-66. doi: 10.1007/s00280-008-0724-8. Epub 2008 Mar 18. Cancer Chemother Pharmacol. 2008. PMID: 18347795 Review.
-
Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.Oncologist. 2008 Dec;13(12):1207-23. doi: 10.1634/theoncologist.2008-0143. Epub 2008 Dec 16. Oncologist. 2008. PMID: 19088324 Review.
-
Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.Future Oncol. 2008 Aug;4(4):483-500. doi: 10.2217/14796694.4.4.483. Future Oncol. 2008. PMID: 18684060 Review.
Cited by
-
Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.Curr Oncol. 2012 Apr;19(2):91-105. doi: 10.3747/co.19.1024. Curr Oncol. 2012. PMID: 22514495 Free PMC article.
-
Ixabepilone: in locally advanced or metastatic breast cancer.Drugs. 2009 Jul 30;69(11):1471-81. doi: 10.2165/00003495-200969110-00006. Drugs. 2009. PMID: 19634925 Review.
-
Triple-negative breast cancer: disease entity or title of convenience?Nat Rev Clin Oncol. 2010 Dec;7(12):683-92. doi: 10.1038/nrclinonc.2010.154. Epub 2010 Sep 28. Nat Rev Clin Oncol. 2010. PMID: 20877296 Review.
-
A structure-activity relationship study on multi-heterocyclic molecules: two linked thiazoles are required for cytotoxic activity.Medchemcomm. 2013 Feb 1;4(2):406-410. doi: 10.1039/C2MD20291C. Epub 2012 Nov 29. Medchemcomm. 2013. PMID: 23524379 Free PMC article.
-
Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets.J Steroid Biochem Mol Biol. 2017 Feb;166:16-27. doi: 10.1016/j.jsbmb.2016.07.006. Epub 2016 Jul 30. J Steroid Biochem Mol Biol. 2017. PMID: 27481707 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
